AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Australia Diabetes Market 2020-2025 by SMBG Device, Continuous Glucose Monitoring (CGM), Insulin Pen, Insulin Pump, Reimbursement, Company Analysis & Forecast - ResearchAndMarkets.com

November 10, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Nov 10, 2020--

The “Australia Diabetes Market, By SMBG Device, Continuous Glucose Monitoring (CGM), Insulin Pen, Insulin Pump, Reimbursement Company Analysis & Forecast” report has been added to ResearchAndMarkets.com’s offering.

ADVERTISEMENT

Australia Diabetes Market is expected to reach USD 2.44 Billion by the year 2025.

Australia ranked seventh in the world for the prevalence of type 1 diabetes in children and 6th highest for incidence. There is also rising prevalence of particularly type 2 diabetes and rising cases of children and adolescents who are now impated by type 2 diabetes in Australia. Type 1 diabetes typically happens in an early age, its a most common form of childhood diabetes although it can occur at any age.

Over 1 million Australians have been diagnosed with diabetes. Australia is dragging behind many western countries in providing affordable access to its people with diabetes to new, proven technologies such as CGM and Insulin pen that can significantly improve the management of diabetes.

The market of Self Monitoring Blood Glucose Device, Continuous Glucose Monitoring (CGM) Device, Insulin Pump, and Insulin Pen are growing due to the rising awareness for diabetes in Australia. Diabetes care in Australia has reached a high level of quality, but there is still an opportunity for further improvement. Diabetes is associated with an uncountable of complications that affect the eyes, feet, kidneys, and cardiovascular health. Besides, diabetes is ranked in the top 10 leading causes of deaths in Australia. Diabetes is a massive challenge to the nation’s health and economy.

Australian Government has essential roles in maintaining access to affordable, high-quality devices and services to support people with diabetes in self-management and treatment. The Australian Government providing support to people with diabetes through the National Diabetes Services Scheme, the Pharmaceutical Benefits Scheme, the Insulin Pump Program, and Medicare.

In 2019, Biocon and Mylan N V launched insulin glargine biosimilar Semglee, first insulin PBS in Australia. In 2019, TAL, a leading Australian life insurance specialist, has launched a specialized product to protect people with diabetes mellitus in Australia.

ADVERTISEMENT

All the 14 Companies Studied in the Report have been Studied from 3 Points

  • Company Overview
  • Recent Developments
  • Financial Insight

Company Analysis

  • B. Braun Melsungen AG
  • Eli Lilly and Company
  • Artsana S.p.A
  • BD
  • Novo Nordisk A/S
  • Owen Mumford Ltd
  • Ypsomed AG
  • Medtronic
  • Insulet Corporation
  • LifeScan Inc.
  • Abbott Laboratories
  • Roche
  • Dexcom Inc

Key Topics Covered:

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

4.1 Growth Driver

4.2 Challenges

5. Australia Diabetes Market

6. Australia Diabetes Population

6.1 Type 1 & Type 2 Diabetes Population and Forecast

7. Market Share Analysis - Australia Diabetic

7.1 By Types

8. Continuous Glucose Monitoring Market (CGM) - Australia Market & Users

8.1 Australia - CGM Market by Components

8.1.1 Glucose Sensor Market & Forecast

8.1.2 CGM Transmitter Market & Forecast

8.2 Australia - CGM User (2011 - 2025)

8.3 CGM Reimbursement in Australia

9. Blood Glucose Device (SMBG) - Australia Market & Users

9.1 Market

9.1.1 Type 1 & Type 2 (Diabetes)

9.2 Test Strips Market and Forecast

9.3 Lancet Market and Forecast

9.4 Meter Market and Forecast

9.5 Blood Glucose Device (SMBG) Users

9.6 Reimbursement of Blood Glucose Devices in Australia

10. Insulin Pen Market & User Analysis

10.1 Insulin Pen User

10.1.1 Disposable Insulin Pen Users

10.1.2 Reusable Insulin Pen Users

10.1.3 Smart Insulin Pen Users

10.2 Insulin Pen Market

10.2.1 Disposable Insulin Pen Market

10.2.2 Reusable Insulin Pen Market

10.2.3 Smart Insulin Pen Market

10.3 Insulin Pen Needle Market

10.4 Reimbursement Policies

11. Insulin Pump Market & Users & Forecast

11.1 Insulin Pump Users & Forecast

11.1.1 Type 1 & Type 2 (Insulin Pump User & Forecast)

11.2 Insulin Pump Market & Forecast

11.2.1 Type 1 & Type 2 (Insulin Pump Market & Forecast)

11.3 Differentiation Points of Insulin Pump Products in Australia

11.3.1 Animas Vibe

11.3.2 Medtronic 530G with Enlite

11.3.3 Insulet OmniPod

11.3.4 Tandem t: slim

11.3.5 Roche Accu-Chek Combo

11.4 Training Model for Patients & HCP - of Medtronic, Animas, Insulet Corp & Tandem Diabetes Care

11.4.1 Medtronic

11.5 Insulet Corporation

11.5.1 Training Structure for New Patients - Insulet Corporation

11.6 Animas Corporation

11.6.1 Training Modules for New Patients

11.6.2 Training Modules for HCP (Health Care Professional)

11.7 Tandem Diabetes Care

11.8 Reimbursement Policies on Insulin Pump

12. Insulin Pen - Company Analysis

12.1 B. Braun Melsungen AG

12.1.1 Overview

12.1.2 Initiatives & Recent Developments

12.1.3 Revenue

12.2 Eli Lilly

12.3 Artsana S.p.A.

12.4 BD

12.5 Novo Nordisk A/S

12.6 Owen Mumford Ltd.

12.7 Ypsomed AG

13. Insulin Pump - Company Analysis

13.1 Medtronic

13.1.1 Overview

13.1.2 Insulin Pump - Product Details

13.1.3 Insulin Pump - Latest Development & Trends

13.1.4 Revenue

13.2 Insulet Corporation

14. SMBG - Company Analysis

14.1 LifeScan Inc.

14.1.1 Overview

14.1.2 Revenue & Forecast

14.2 Abbott Laboratories

15. CGM - Company Analysis

15.1 Dexcom Inc

15.1.1 Overview

15.1.2 Recent Development

15.1.3 Revenue& Forecast

15.2 Abbott Laboratories

15.3 Roche

For more information about this report visit https://www.researchandmarkets.com/r/8v2lud

View source version on businesswire.com:https://www.businesswire.com/news/home/20201110005622/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH DIABETES

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 11/10/2020 06:04 AM/DISC: 11/10/2020 06:04 AM

http://www.businesswire.com/news/home/20201110005622/en